Press releases

You will be able to find all of our recent and archived news announcements. Our press releases are intended for business journalists and analysts/investors.

GSK’s Bexsero®▼achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children

GSK today presented new data for its meningococcal group B vaccine, Bexsero®,1 [Meningococcal group B Vaccine (rDNA, component, adsorbed)] comparing safety and immunogenicity with different dosing schedules in infants and young children, at the annual meeting of the European Society for Paediatric Infectious Diseases (ESPID).

Read more - GSK’s Bexsero®▼achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children Read more

European agency endorses antiseptic gel, developed through GSK and Save the Children partnership, for newborn umbilical cord infections in developing countries

Major milestone for the GSK and Save the Children partnership and its mission to help save the lives of children in the world’s poorest communities

Read more - European agency endorses antiseptic gel, developed through GSK and Save the Children partnership, for newborn umbilical cord infections in developing countries Read more